FDA fast-tracks EO2463 immunotherapy for follicular lymphoma, promising a new treatment option backed by positive trial data ...
A study published in Cancer Discovery finds that combining an epigenetic therapy with an anti-PD-1 antibody, which uses the ...
Covers low tumor burden “watch-and-wait” setting, an unmet medical needRegistrational Phase 3 watch-and-wait to start in 2026EO2463 has broad ...
News Medical on MSN
New Combination Therapy Shows Promise For Aggressive Lymphoma Resistant To Immunotherapy
Combining an epigenetic therapy with an anti-PD-1 antibody, which uses the body's natural response to viral infections, showed promising ...
Enterome has received fast track designation from the US Food and Drug Administration for its lead OncoMimics immunotherapy EO2463, targeting follicular lymphoma in the low tumour burden ...
Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc.
At Ochsner Cancer Center of Acadiana, people diagnosed with blood cancers find more than the latest treatments — they also ...
The trial laid the foundation for the Comparative Immunotherapy Program — a program launched a year ago to tap into Penn’s ...
The indolent lymphoma market is witnessing steady growth driven by the increasing prevalence of slow-growing non-Hodgkin lymphomas and rising awareness about early diagnosis.
Neurocognitive functioning declines across central nervous system cancers, shaped by tumor type, location, and treatment. A ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results